Overview
ARTL market data
Price History
ARTL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$37.55 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.96 – $85.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.5 · P/B 1.20.
Company news
Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical PharmacologyBenzinga · Jul 22, 2026, 12:41 PM
Artelo Biosciences Announces Oral Administration Of ART26.12 Lowers Osteoarthritis-Associated Pain Behaviors Over 4-Week Testing; Shows Efficacy To NaproxenBenzinga · Jul 16, 2026, 12:50 PM
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026Globenewswire Inc · Jul 14, 2026, 1:15 PM
Artelo Biosciences Reports Preclinical Results For ART27.13 in Cancer-Related Neuropathic Pain; Findings Suggest Broader Utility In Cancer Supportive Care, Building On Interim Findings From CAReS Phase 2 Clinical Study Which Demonstrated Improvements In Body Weight, Lean Body Mass And Activity LevelsBenzinga · Jul 13, 2026, 1:03 PM
Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivity Associated With Nerve Injury; Decreased Spontaneous Pain-Related BehaviorsBenzinga · Jul 1, 2026, 12:50 PM
Artelo Biosciences Identifies Lipid Pathway Link For ART26.12 In Multi-Omics Cancer Research Presentation At The CRS 2026 Annual SymposiumBenzinga · Jun 30, 2026, 1:05 PM
Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 InhibitorBenzinga · Jun 29, 2026, 12:55 PM
8-K filing — ARTELO BIOSCIENCES, INC. (ARTL)SEC EDGAR · May 27, 2026, 8:39 PM
Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 ResultsBenzinga · May 27, 2026, 6:35 PM
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 ResultsBenzinga · May 27, 2026, 2:40 PM